The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects

Bowen Lu, Jing Ming Lim, Boyue Yu, Siyuan Song, Praveen Neeli, Navid Sobhani, Pavithra K, Srinivasa Reddy Bonam, Rajendra Kurapati, Junnian Zheng, Dafei Chai

Frontiers of Immunology, vol. 15(1332939), 2024

Artificial intelligence-powered discovery of small molecules inhibiting CTLA-4 in cancer

Navid Sobhani, Dana Rae Tardiel-Cyril, Dafei Chai, Daniele Generali, Jian-Rong Li, Jonathan Vazquez-Perez, Jing Ming Lim, Rachel Morris, Zaniqua N Bullock, Aram Davtyan, Chao Cheng, William K Decker, Yong Li

British Journal of Cancer Reports, vol. 2, 2024

Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses

Alberto D'Angelo, Huseyin Kilili, Robert Chapman, Daniele Generali, Ingeborg Tinhofer, Stefano Luminari, Benedetta Donati, Alessia Ciarrocchi, Riccardo Giannini, Roberto Moretto, Chiara Cremolini, Filippo Pietrantonio, Navid Sobhani, Debora Bonazza, Robert Prins, Seung Geun Song, Yoon Kyung Jeon, Giuseppina Pisignano, Mattia Cinelli, Stefan Bagby, Araxi O Urrutia

PLoS One, vol. 18(1), 2023, pp. e0280364

Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair

Monica Ganzinelli, Federica Guffanti, Anna Ianza, Navid Sobhani, Sergio Crovella, Fabrizio Zanconati, Cristina Bottin, Marco Confalonieri, Stefano Fumagalli, Alessandra Guglielmi, Daniele Generali, Giovanna Damia

Cancers, vol. 15, 2023, p. 4309

The co-delivery of adenovirus-based immune checkpoint vaccine elicits a potent anti-tumor effect in renal carcinoma

Nan Jiang, Yanyan Zheng, Jiage Ding, Jiawei Wang, Fei Zhu, Meng Wang, Navid Sobhani, Praveen Neeli, Gang Wang, Hailong Li, Junnian Zheng, Dafei Chai

NPJ Vaccines, vol. 8(109), 2023

The power of whole genomic sequencing in biomedical research and clinical applications

Navid Sobhani, Alberto D'Angelo, Felipe Umper Conter, Rachel Morris, Yong Li

Reference Module in Biomedical Sciences, Elsevier, 2023

Cancer management during the COVID‑19 world pandemic

Navid Sobhani, Giuseppina Mondani, Giandomenico Roviello, Martina Catalano, Marianna Sirico, Alberto D’Angelo, Bruna Scaggiante, Daniele Generali

Cancer Immunology, Immunotherapy, 2023

Biomarkers of Prediction of Immunotherapy and Updates on CTLA-4 Therapy

Navid Sobhani, Raheleh Roudi, Alberto D'Angelo, Daniele Generali

Springer Nature, 2023, pp. 1-35

Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report

Navid Sobhani, Victoria Bouchè, Giovanni Aldegheri, Andrea Rocca, Alberto D'Angelo, Fabiola Giudici, Cristina Bottin, Carmine Antonio Donofrio, Maurizio Pinamonti, Benvenuto Ferrari, Stefano Panni, Marika Cominetti, Jahard Aliaga, Marco Ungari, Antonio Fioravant, Fabrizio Zanconati, Daniele Generali

Biomedicines, vol. 11(2), 2023, p. 311

Comparison of DNA vaccines with AS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2

Praveen Neeli, Dafei Chai, Xu Wang, Navid Sobhani, George Udeani, Yong Li

iScience, vol. 26(7), 2023, p. 107120

HMGB1/GPC3 dual targeting vaccine induces dendritic cells-mediated CD8+T cell immune response and elicits potential therapeutic effect in hepatocellular carcinoma

Xiaoqing Shi, Jiage Ding, Yanyan Zheng, Jiawei Wang, Navid Sobhani, Praveen Neeli, Gang Wang, unnian Zheng, Dafei Chai

iScience, vol. 26(3), 2023, p. 106143

Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study

Alberto D'Angelo, Fabiola Giudici, Robert Chapman, Jacob Darlow, Huseyin Kilili, Navid Sobhani, Mattia Cinelli, Maria Rosa Cappelletti, Carla Strina, Manuela Milani, Daniele Generali

Current Issues Molecular Biology, vol. 44(9), 2022, pp. 4255-4267

An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next

Alberto D'Angelo, Robert Chapman, Marianna Sirico, Navid Sobhani, Martina Catalano, Enrico Mini, Giandomenico Roviello

Cancer Chemotherapy and Pharmacology, vol. 90(3), 2022, pp. 191-205

IFI35 Promotes Renal Cancer Progression by Inhibiting pSTAT1/pSTAT6-Dependent Autophagy

Dafei Chai, Shang Yuchen Shi, Navid Sobhani, Jiage Ding, Zichun Zhang, Nan Jiang, Gang Wang, Minle Li, Hailong Li, Junnian Zheng, Jin Bai

Cancers, vol. 14(12), 2022, p. 2861

The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment

Mohammad Hadi Abbasian, Ali M Ardekani, Navid Sobhani, Raheleh Roudi

Cancers, vol. 14(20), 2022, p. 5144

Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials

Navid Sobhani, Bruna Scaggiante, Rachel Morris, Dafei Chai, Martina Catalano, Dana Rae Tardiel-Cyril, Praveen Neeli, Giandomenico Roviello, Giuseppina Mondani, Yong Li

Cancer Treatment Reviews, vol. 109, 2022, p. 102429

Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer

Navid Sobhani, Richard Chahwan, Raheleh Roudi, Rachel Morris, Stefano Volinia, Dafei Chai, Alberto D'Angelo, Daniele Generali

Cancers, vol. 14(12), 2022, p. 2952

C1QBP regulates mitochondrial plasticity to impact tumor progression and antitumor immune response

Qiping Wang, Dafei Chai, Navid Sobhani, Nan Sun, Praveen Neeli, unnian Zheng, Hui Tian

Frontiers Physiology, vol. 14, 2022, p. 1012112

Cancer/testis antigens: from serology to mRNA cancer vaccine

Chunmei Fan, Hongke Qu, Xu Wang, Navid Sobhani, Leiming Wang, Shuanglin Liu, Wei Xiong, Zhaoyang Zeng, Yong Li

Seminars Cancer Biology, vol. 26, 2021, pp. 218-231

Advances in anti-BRAF therapies for lung cancer

Giandomenico Roviello, Alberto D'Angelo, Marianna Sirico, Matteo Pittacolo, Felipe Umpierre Conter, Navid Sobhani

vol. 39(3), 2021, pp. 879-890

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer

Navid Sobhani, Anne Fassl, Giuseppina Mondani, Daniele Generali, Tobias Otto

Cells, vol. 10(2), 2021, p. 293

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy

Navid Sobhani, Dana Rae Tardiel-Cyril, Daniele Generali Aram Davtyan 2, Raheleh Roudi, Yong Li

Cancers, vol. 13(6), 2021, p. 1440

p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis

Navid Sobhani, Giandomenico Roviello, Alberto D'Angelo, Raheleh Roudi, Praveen Kumar Neeli, Daniele Generali

Molecules, vol. 26(20), 2021, p. 6215

AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption

Navid Sobhani, Praveen Kumar Neeli, Alberto D'Angelo, Matteo Pittacolo, Marianna Sirico, Ilaria Camilla Galli, Giandomenico Roviello, Gabriella Nesi

International Journal of Molecular Science, vol. 22(11), 2021, p. 5515

Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects

Raheleh Roudi, Alberto D'Angelo, Marianna Sirico, Navid Sobhani

International Immunopharmacol ., vol. 101(Pt A), 2021, p. 108322

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies

Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello

Cancers, vol. 12(11), 2020, p. 3293

Cabozantinib as a second-line treatment option in hepatocellular carcinoma

Alberto D'Angelo, Navid Sobhani, Stefan Bagby, Andrea Casadei-Gardini, Giandomenico Roviello

Expert Review Clinical Pharmacology, vol. 13(6), 2020, pp. 623-629

Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study

Francesco Schettini, Navid Sobhani, Anna Ianza, Tiziana Triulzi, Alfredo Molteni, Maria Chiara Lazzari, Carla Strina, Manuela Milani, Silvia Paola Corona, Marianna Sirico, Ottavia Bernocchi, Fabiola Giudici, Maria Rosaria Cappelletti, Eva Ciruelos, Guy Jerusalem, Sherine Loi, Stephen B Fox, Daniele Generali

Breast Cancer Research Treatment, vol. 184(2), 2020, pp. 421-431

Corticosteroid switch after progression on abiraterone acetate plus prednisone

Giandomenico Roviello, Navid Sobhani, Silvia Paola Corona, Alberto D'Angelo

International Journal of Clinical Oncology, vol. 25(2), 2020, pp. 240-246

Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer

Marianna Sirico, Ottavia Bernocchi, Navid Sobhani, Fabiola Giudici, Silvia P Corona, Claudio Vernieri, Federico Nichetti, Maria Rosa Cappelletti, Manuela Milani, Carla Strina, Valeria Cervoni, Giuseppina Barbieri, Nicoletta Ziglioli, Martina Dester, Giulia Valeria Bianchi, Filippo De Braud, Daniele Generali

Cancers, vol. 12(11), 2020, p. 3314

Mutant p53 as an Antigen in Cancer Immunotherapy

Navid Sobhani, Alberto D'Angelo, Xu Wang, Ken H Young, Daniele Generali, Yong Li

International Journal of Molecular Science, vol. 21(11), 2020, p. 4087

Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer

Navid Sobhani, Marianna Sirico, Daniele Generali, Fabrizio Zanconati, Bruna Scaggiante

World Journal of Clinical Oncology, vol. 11(7), 2020, pp. 450-463

Immune-gene signature: a new tool for patient selection for checkpoint inhibitors?

Navid Sobhani, Silvia P Corona, Giandomenico Roviello, Stefan Bagby, Alberto D'Angelo, Giandomenico Iezzi, Daniele Generali

Future Oncology, vol. 16(19), 2020, pp. 1327-1330

MR1-Restricted T Cells in Cancer Immunotherapy

Pedro Flores-Villanueva, Navid Sobhani, Xu Wang, Yong Li

Cancers, vol. 12(8), 2020, p. 2145

The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments

Sobhani Navid, Chunmei Fan, Pedro O Flores-Villanueva, Daniele Generali, Yong Li

International Journal of Molecular Science, vol. 21(6), 2020, p. 2011

Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma

Alberto D'Angelo, Navid Sobhani, Giandomenico Roviello, Stefan Bagby, Deborah Bonazza, Cristina Bottin, Fabiola Giudici, Fabrizio Zanconati, Nicolo De Manzini, Alessandra Guglielmi, Daniele Generali

PLoS One, vol. 14(8), 2019, pp. e0219566

Avelumab in gastric cancer

Giandomenico Roviello, Alberto D'Angelo, Daniele Generali, Matteo Pittacolo, Monica Ganzinelli, Giandomenica Iezzi, Nicolò de Manzini, Navid Sobhani

Immunotherapy, vol. 11(9), 2019, pp. 759-768

The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer-a commentary on the E5103 randomized phase III clinical study

Giandomenico Roviello, Daniele Generali, Navid Sobhani

Translational Cancer Research, vol. 8(Suppl 2 ), 2019, pp. S94-S96

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer

Navid Sobhani, Alberto D'Angelo, Matteo Pittacolo, Giandomenico Roviello, Anna Miccoli, Silvia Paola Corona, Ottavia Bernocchi, Daniele Generali, Tobias Otto

Cells, vol. 8(4), 2019, p. 321

Lenvatinib for the treatment of renal cell carcinoma

Giandomenico Roviello, Silvia Paola Corona, Giovanni Bozza, Michele Aieta, Daniele Generali, Maria Grazia Rodriquenz, Anna Maria Mileo, Marco Imperatori, Anna Ianza, Raffaele Conca, Navid Sobhani

Expert Opinion Investigational Drugs, vol. 27(5), 2018, pp. 507-512

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer

Navid Sobhani, Anna Ianza, Alberto D'Angelo, Giandomenico Roviello, Fabiola Giudici, Marina Bortul, Fabrizio Zanconati, Cristina Bottin, Daniele Generali

Cells, vol. 7(7), 2018, p. 76

Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer

Navid Sobhani, Daniele Generali, Alberto D'Angelo, Michele Aieta, Giandomenico Roviello

Invest New Drugs, vol. 36(6), 2018, pp. 1133-1137

Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer

Navid Sobhani, Daniele Generali, Fabrizio Zanconati, Marina Bortul, Bruna Scaggiante

World Journal of Clinical Oncology, vol. 9(8), 2018, pp. 172-179

The prognostic value of PI3K mutational status in breast cancer: A meta-analysis

Navid Sobhani, Giandomenico Roviello, Silvia P Corona, Maurizio Scaltriti, Anna Ianza, Marina Bortul, Fabrizio Zanconati, Daniele Generali

Journal of Cellular Biochemistry, vol. 119(6), 2018, pp. 4287-4292

Bevacizumab in small cell lung cancer

Giandomenico Roviello, Navid Sobhani, Daniele Generali

Annals of Translational Medicine, vol. 5(17), 2017, p. 361

C32Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: a literature based meta-analysis of randomized trials

Giandomenico Roviello, O. Pagani, F. Meani, Carla Strina, Daniele Zanoni, Manuela Milani, Navid Sobhani, Anna Ianza, Marina Bortul, Fabrizio Zanconati, Pietro Rossellini, Daniele Generali

Annals of Oncology , vol. 28(VI34), 2017, (suppl_6)

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy

Navid Sobhani, Daniele Generali, Giandomenico Roviello

EBioMedicine, vol. 22, 2017, pp. 18-19

Advances in systemic therapy for malignant mesothelioma: future perspectives

Navid Sobhani, Silvia Paola Corona, Deborah Bonazza, Anna Ianza, Tania Pivetta, Giandomenico Roviello, Maurizio Cortale, Alessandra Guglielmi, Fabrizio Zanconati, Daniele Generali

Future of Oncology, vol. 13(23), 2017, pp. 2083-2101

Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma

Navid Sobhani, Silvia P Corona, Fabrizio Zanconati, Daniele Generali

Genes Cancer, vol. 8(3-4), 2017, pp. 495-496